Devicetherapie in der Herzinsuffizienz – wie richtig einsetzen?

Zusammenfassung

Die Devicetherapie hat sich in der zurückliegenden Dekade zu einem der wesentlichen Pfeiler in der Behandlung der systolischen Herzinsuffizienz entwickelt; insbesondere der Schutz vor lebensbedrohlichen Tachyarrhythmien mittels implantierbarem Kardioverter-Defibrillator (ICD) wie auch die kardiale Resynchronisationstherapie (CRT) sind heutzutage für viele Patienten etablierter Standard. Viele weitere technische Errungenschaften befinden sich in der klinischen Erprobungsphase. Dieser Artikel soll einen Überblick geben über die schon etablierten Devices in der Herzinsuffizienzbehandlung und stellt einige innovative, z. T. vielversprechende neue Ansätze in der „Device“-basierten Herzinsuffizienztherapie vor.

Abstract

In the last deacades, device therapy in the treatment of systolic heart failure has become one of the pivotal pillars. First and foremost, implantable cardioverter defibrillators with or without resynchronization therapy have been shown to be superior to best medical treatment in certain conditions and have now been broadly adopted into daily clinical practice. Numerous additional technical innovations are currently undergoing clinical evaluation in heart failure studies. This review sums up the current standard of established therapies and sheds light on evolving device therapies and its future potential in the treatment of heart failure.

Schlüsselwörter

kardiale Kontraktilitätsmodulation - implantierbarer Kardioverter-Defibrillator - kardiale Resynchronisationstherapie

Key words

cardiac contractility modulation - implantable cardioverter defibrillator - cardiac resynchronization therapy

• Literatur

• 1 Moss AJ, Zareba W, Hall WJ. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883
• 2 Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
• 3 Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of medical therapy, pacing, and defibrillation in chronic heart failure (companion) trial. Companion steering committee and companion clinical investigators. J Card Fail 2000; 6: 276-285
• 4 Cleland JG, Daubert JC, Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
• 5 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200
• 6 Kober L, Thune JJ, Nielsen JC. et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375: 1221-1230
• 7 Steinbeck G, Andresen D, Seidl K. et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427-1436
• 8 Ruschitzka F, Abraham WT, Singh JP. et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405
• 9 Steffel J, Robertson M, Singh JP. et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015; 36: 1983-1989
• 10 Gasparini M, Leclercq C, Lunati M. et al. Cardiac resynchronization therapy in patients with atrial fibrillation: The CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1: 500-507
• 11 Cunnington C, Kwok CS, Satchithananda DK. et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block qrs morphology: Meta-analysis of randomised controlled trials. Heart 2015; 101: 1456-1462
• 12 Goldenberg I, Kutyifa V, Klein HU. et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370: 1694-1701
• 13 Tang AS, Wells GA, Talajic M. et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2395
• 14 Birnie DH, Ha A, Higginson L. et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013; 6: 1190-1198
• 15 Kutyifa V, Stockburger M, Daubert JP. et al. PR interval identifies clinical response in patients with non-left bundle branch block: A multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy substudy. Circ Arrhythm Electrophysiol 2014; 7: 645-651
• 16 Van Bommel RJ, Mollema SA, Borleffs CJ. et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2011; 57: 549-555
• 17 Kirubakaran S, Ladwiniec A, Arujuna A. et al. Male gender and chronic obstructive pulmonary disease predict a poor clinical response in patients undergoing cardiac resynchronisation therapy. Int J Clin Pract 2011; 65: 281-288
• 18 Leong DP, Hoke U, Delgado V. et al. Right ventricular function and survival following cardiac resynchronisation therapy. Heart 2013; 99: 722-728
• 19 Hsu JC, Solomon SD, Bourgoun M. et al. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol 2012; 59: 2366-2373
• 20 Cleland JG, Abraham WT, Linde C. et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547-3556
• 21 Garrigue S, Jais P, Espil G. et al. Comparison of chronic biventricular pacing between epicardial and endocardial left ventricular stimulation using doppler tissue imaging in patients with heart failure. Am J Cardiol 2001; 88: 858-862
• 22 Ploux S, Strik M, van Hunnik A. et al. Acute electrical and hemodynamic effects of multisite left ventricular pacing for cardiac resynchronization therapy in the dyssynchronous canine heart. Heart Rhythm 2014; 11: 119-125
• 23 Forleo GB, Santini L, Giammaria M. et al. Multipoint pacing via a quadripolar left-ventricular lead: Preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy (IRON-MPP). Europace 2016;
• 24 Pappone C, Rosanio S, Oreto G. et al. Cardiac pacing in heart failure patients with left bundle branch block: Impact of pacing site for optimizing left ventricular resynchronization. Ital Heart J 2000; 1: 464-469
• 25 Lenarczyk R, Kowalski O, Pruszkowska-Skrzep P. et al. Triple site biventricular pacing in a patient with congestive heart failure and severe mechanical dyssynchrony. J Interv Card Electrophysiol 2007; 18: 187-190
• 26 Rogers DP, Lambiase PD, Lowe MD. et al. A randomized double-blind crossover trial of triventricular versus biventricular pacing in heart failure. Eur J Heart Fail 2012; 14: 495-505
• 27 Kadish A, Nademanee K, Volosin K. et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161: 329-337.e1–2
• 28 Abraham WT, Adamson PB, Bourge RC. et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet 2011; 377: 658-666
• 29 Abraham WT, Stevenson LW, Bourge RC. et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016; 387: 453-461
• 30 Bohm M, Drexler H, Oswald H. et al. Fluid status telemedicine alerts for heart failure: A randomized controlled trial. Eur Heart J 2016; 37: 3154-3163
• 31 Zipes DP, Neuzil P, Theres H. et al. Determining the feasibility of spinal cord neuromodulation for the treatment of chronic systolic heart failure: The DEFEAT-HF study. JACC Heart Fail 2016; 4: 129-136
• 32 Gold MR, Van Veldhuisen DJ, Hauptman PJ. et al. Vagus nerve stimulation for the treatment of heart failure: The INOVATE-HF trial. J Am Coll Cardiol 2016; 68: 149-158
• 33 Ricci RP, Morichelli L, Santini M. Home monitoring remote control of pacemaker and implantable cardioverter defibrillator patients in clinical practice: Impact on medical management and health-care resource utilization. Europace 2008; 10: 164-170
• 34 Fauchier L, Sadoul N, Kouakam C. et al. Potential cost savings by telemedicine-assisted long-term care of implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol 2005; 28 (Suppl. 01) S255-S259
• 35 Klersy C, De Silvestri A, Gabutti G. et al. Economic impact of remote patient monitoring: An integrated economic model derived from a meta-analysis of randomized controlled trials in heart failure. Eur J Heart Fail 2011; 13: 450-459
• 36 Varma N, Epstein AE, Irimpen A. et al. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010; 122: 325-332
• 37 Guedon-Moreau L, Chevalier P, Marquie C. et al. Contributions of remote monitoring to the follow-up of implantable cardioverter-defibrillator leads under advisory. Eur Heart J 2010; 31: 2246-2252
• 38 Hindricks G, Taborsky M, Glikson M. et al. Implant-based multiparameter telemonitoring of patients with heart failure (in-time): A randomised controlled trial. Lancet 2014; 384: 583-590
• 39 Parthiban N, Esterman A, Mahajan R. et al. Remote monitoring of implantable cardioverter-defibrillators: A systematic review and meta-analysis of clinical outcomes. J Am Coll Cardiol 2015; 65: 2591-2600
• 40 Kuschyk J, Borggrefe M. Elektrische Therapie der Herzinsuffizienz. Kardiologie up2date 2013; 9: 37-56